Pharmacogenetics, pharmacogenomics and epigenetics of Nrf2-regulated xenobioticmetabolizing enzymes and transporters by dietary phytochemical and cancer chemoprevention

Current Drug Metabolism

Volumn 14, Issue 6, 2013, Pages 688-694

  Wu, Tien Yuan ^a   Khor, Tin Oo ^a   Lee, Jong Hun ^a   Cheung, Ka Lung ^a   Shu, Limin ^a   Chen, Chi ^b   Kong, Ah Ng ^a  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Chemoprevention; Epigenetics; Genetic polymorphism; Nuclear factor erythroid 2 related factor 2 (Nrf2); Pharmacogenomics; Xenobiotic metabolizing enzymes (XMEs)

Indexed keywords

ENZYME; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; XENOBIOTIC METABOLIZING ENZYME;

ARTICLE; CANCER PREVENTION; CARCINOGENICITY; CHEMOPROPHYLAXIS; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; OXIDATIVE STRESS; PHARMACOGENETICS; PHARMACOGENOMICS; PHYTOCHEMISTRY; SIGNAL TRANSDUCTION;

ANIMALS; ANTICARCINOGENIC AGENTS; EPIGENOMICS; HUMANS; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS; NF-E2-RELATED FACTOR 2; OXIDOREDUCTASES; PHYTOCHEMICALS; POLYMORPHISM, GENETIC; TRANSFERASES; XENOBIOTICS;

EID: 84882321036     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211314060005     Document Type: Article

References (82)

1. Mandlekar, S.; Hong, J. L.; Kong, A. N. Modulation of metabolic enzymes by dietary phytochemicals: a review of mechanisms underlying beneficial versus unfavorable effects. Curr. Drug Metab., 2006, 7(6), 661-75.
2. Pool-Zobel, B.; Veeriah, S.; Bohmer, F. D. Modulation of xenobiotic metabolising enzymes by anticarcinogens-focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis. Mutat. Res., 2005, 591(1-2), 74-92.
3. Xu, C.; Li, C. Y.; Kong, A. N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res., 2005, 28(3), 249-68.
4. Jana, S.; Mandlekar, S. Role of phase II drug metabolizing enzymes in cancer chemoprevention. Curr. Drug Metab., 2009, 10(6), 595-616.
5. You, G. A. M. M. E. Drug transporters: molecular characterization and role in drug disposition. John Wiley & Sons, Inc.: Hoboken, New Jersey, 2007.
6. Baker, E. K.; El-Osta, A. MDR1, chemotherapy and chromatin remodeling. Cancer Biol. Ther., 2004, 3(9), 819-24.
7. Baker, E. K.; Johnstone, R. W.; Zalcberg, J. R.; El-Osta, A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene, 2005, 24(54), 8061-75.
8. Jeong, W. S.; Jun, M.; Kong, A. N. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid. Redox Signal., 2006, 8(1-2), 99-106.
9. Goldberg, A. D.; Allis, C. D.; Bernstein, E. Epigenetics: a landscape takes shape. Cell, 2007, 128(4), 635-8.
10. Gomez, A.; Ingelman-Sundberg, M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin. Pharmacol. Ther., 2009, 85(4), 426-30.
11. Esteller, M. Epigenetics in cancer. N. Engl. J. Med., 2008, 358(11), 1148-59.
12. Rieder, M. J.; Livingston, R. J.; Stanaway, I. B.; Nickerson, D. A. The environmental genome project: reference polymorphisms for drug metabolism genes and genome-wide association studies. Drug Metab. Rev., 2008, 40(2), 241-61.
13. Efferth, T.; Volm, M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther., 2005, 107(2), 155-76.
14. Reddy, A. J.; Christie, J. D.; Aplenc, R.; Fuchs, B.; Lanken, P. N.; Kleeberger, S. R. Association of human NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphism with development of acute lung injury. J. Cell Mol. Med., 2009, 13(8B), 1784-91.
15. Shen, G.; Kong, A. N. Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm. Drug Dispos., 2009, 30(7), 345-55.
16. Surh, Y. J., Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer, 2003, 3(10), 768-80.
17. Khor, T. O.; Huang, M. T.; Kwon, K. H.; Chan, J. Y.; Reddy, B. S.; Kong, A. N. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res., 2006, 66(24), 11580-4.
18. Chanas, S. A.; Jiang, Q.; McMahon, M.; McWalter, G. K.; McLellan, L. I.; Elcombe, C. R.; Henderson, C. J.; Wolf, C. R.; Moffat, G. J.; Itoh, K.; Yamamoto, M.; Hayes, J. D. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem. J., 2002, 365(Pt 2), 405-16.
19. Thimmulappa, R. K.; Mai, K. H.; Srisuma, S.; Kensler, T. W.; Yamamoto, M.; Biswal, S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res., 2002, 62(18), 5196-203.
20. Barve, A.; Khor, T. O.; Nair, S.; Lin, W.; Yu, S.; Jain, M. R.; Chan, J. Y.; Kong, A. N. Pharmacogenomic profile of soy isoflavone concentrate in the prostate of Nrf2 deficient and wild-type mice. J. Pharm. Sci., 2008, 97(10), 4528-45.
21. Nair, S.; Xu, C.; Shen, G.; Hebbar, V.; Gopalakrishnan, A.; Hu, R.; Jain, M. R.; Lin, W.; Keum, Y. S.; Liew, C.; Chan, J. Y.; Kong, A. N. Pharmacogenomics of phenolic antioxidant butylated hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. Pharm. Res., 2006, 23(11), 2621-37.
22. Shen, G.; Xu, C.; Hu, R.; Jain, M. R.; Gopalkrishnan, A.; Nair, S.; Huang, M. T.; Chan, J. Y.; Kong, A. N. Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol. Cancer Ther., 2006, 5(1), 39-51.
23. Thimmulappa, R. K.; Rangasamy, T.; Alam, J.; Biswal, S. Dibenzoylmethane activates Nrf2-dependent detoxification pathway and inhibits benzo(a)pyrene induced DNA adducts in lungs. Med. Chem., 2008, 4(5), 473-81.
24. Maher, J. M.; Cheng, X.; Slitt, A. L.; Dieter, M. Z.; Klaassen, C. D. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Dispos., 2005, 33(7), 956-62.
25. Klaassen, C. D.; Slitt, A. L. Regulation of hepatic transporters by xenobiotic receptors. Curr. Drug Metab., 2005, 6(4), 309-28.
26. Aleksunes, L. M.; Slitt, A. L.; Maher, J. M.; Augustine, L. M.; Goedken, M. J.; Chan, J. Y.; Cherrington, N. J.; Klaassen, C. D.; Manautou, J. E. Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol. Appl. Pharmacol., 2008, 226(1), 74-83.
27. Xu, S.; Weerachayaphorn, J.; Cai, S. Y.; Soroka, C. J.; Boyer, J. L. Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 299(1), G126-35.
28. Gelhaus, S. L.; Gilad, O.; Hwang, W. T.; Penning, T. M.; Blair, I. A. Multidrug resistance protein (MRP) 4 attenuates benzo[a]pyrene-mediated DNA-adduct formation in human bronchoalveolar H358 cells. Toxicol. Lett., 2012, 209(1), 58-66.
29. Adachi, T.; Nakagawa, H.; Chung, I.; Hagiya, Y.; Hoshijima, K.; Noguchi, N.; Kuo, M. T.; Ishikawa, T., Nrf2-dependent and-independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J. Exp. Ther. Oncol., 2007, 6(4), 335-48.
30. Hagiya, Y.; Adachi, T.; Ogura, S.; An, R.; Tamura, A.; Nakagawa, H.; Okura, I.; Mochizuki, T.; Ishikawa, T. Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapy. J. Exp. Ther. Oncol., 2008, 7(2), 153-67.
31. Brinkmann, U.; Eichelbaum, M., Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J., 2001, 1(1), 59-64.
32. Brinkmann, U.; Roots, I.; Eichelbaum, M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov. Today, 2001, 6(16), 835-839.
33. Guha, N.; Chang, J. S.; Chokkalingam, A. P.; Wiemels, J. L.; Smith, M. T.; Buffler, P. A. NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am. J. Epidemiol., 2008, 168(11), 1221-32.
34. Guillemette, C.; Levesque, E.; Harvey, M.; Bellemare, J.; Menard, V. UGT genomic diversity: beyond gene duplication. Drug Metab. Rev., 42(1), 22-42.
35. Lee, S. A.; Fowke, J. H.; Lu, W.; Ye, C.; Zheng, Y.; Cai, Q.; Gu, K.; Gao, Y. T.; Shu, X. O.; Zheng, W. Cruciferous vegetables, the GSTP1 Ile105Val genetic polymorphism, and breast cancer risk. Am. J. Clin. Nutr., 2008, 87(3), 753-60.
36. Cheung, K. L.; Khor, T. O.; Huang, M. T.; Kong, A. N. Differential in vivo mechanism of chemoprevention of tumor formation in azoxymethane/dextran sodium sulfate mice by PEITC and DBM. Carcinogenesis, 31(5), 880-5.
37. Font, A.; Sanchez, J. M.; Taron, M.; Martinez-Balibrea, E.; Sanchez, J. J.; Manzano, J. L.; Margeli, M.; Richardet, M.; Barnadas, A.; Abad, A.; Rosell, R. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest. New Drugs, 2003, 21(4), 435-43.
38. Hanene, C.; Jihene, L.; Jamel, A.; Kamel, H.; Agnes, H. Association of GST genes polymorphisms with asthma in Tunisian children. Mediators Inflamm., 2007, 2007, 19564.
39. Gupta, E.; Lestingi, T. M.; Mick, R.; Ramirez, J.; Vokes, E. E.; Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 1994, 54(14), 3723-5.
40. Lee, J. H.; Khor, T. O.; Shu, L.; Su, Z.-Y.; Fuentes, F.; Kong, A.-N. T. Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol. Ther., 2013, 137(2), 153-171.
41. Wu, T. Y.; Khor, T. O.; Saw, C. L.; Loh, S. C.; Chen, A. I.; Lim, S. S.; Park, J. H.; Cai, L.; Kong, A. N. Anti-inflammatory/Anti-oxidative Stress Activities and Differential Regulation of Nrf2-Mediated Genes by Non-Polar Fractions of Tea Chrysanthemum zawadskii and Licorice Glycyrrhiza uralensis. AAPS J., 2011, 13(1), 1-13.
42. Sharma, S.; Kelly, T. K.; Jones, P. A. Epigenetics in cancer. Carcinogenesis, 2010, 31(1), 27-36.
43. Baylin, S. B.; Herman, J. G.; Graff, J. R.; Vertino, P. M.; Issa, J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 1998, 72, 141-96.
44. Belanger, A. S.; Tojcic, J.; Harvey, M.; Guillemette, C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Mol. Biol., 2010, 11, 9
45. Yu, S.; Khor, T. O.; Cheung, K. L.; Li, W.; Wu, T. Y.; Huang, Y.; Foster, B. A.; Kan, Y. W.; Kong, A. N. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS One, 2010, 5(1), e8579.
46. Sharma, G.; Mirza, S.; Parshad, R.; Srivastava, A.; Datta Gupta, S.; Pandya, P.; Ralhan, R. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin. Biochem., 2010, 43(4-5), 373-9.
47. To, K. K.; Zhan, Z.; Bates, S. E. Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol. Cell Biol., 2006, 26(22), 8572-85.
48. Bram, E. E.; Stark, M.; Raz, S.; Assaraf, Y. G. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia, 2009, 11(12), 1359-70.
49. Robey, R. W.; To, K. K.; Polgar, O.; Dohse, M.; Fetsch, P.; Dean, M.; Bates, S. E. ABCG2: a perspective. Adv. Drug Deliv. Rev., 2009, 61(1), 3-13.
50. Kacevska, M.; Ivanov, M.; Ingelman-Sundberg, M. Perspectives on epigenetics and its relevance to adverse drug reactions. Clin. Pharmacol. Ther., 2011, 89(6), 902-7.
51. Hussain, S. P.; Harris, C. C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer, 2007, 121(11), 2373-80.
52. Khor, T. O.; Yu, S.; Kong, A. N. Dietary cancer chemopreventive agents-targeting inflammation and Nrf2 signaling pathway. Planta Med., 2008, 74(13), 1540-7.
53. Xu, C.; Huang, M. T.; Shen, G.; Yuan, X.; Lin, W.; Khor, T. O.; Conney, A. H.; Kong, A. N. Inhibition of 7, 12-dimethylbenz(a) anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res., 2006, 66(16), 8293-6.
54. Shen, G.; Jeong, W. S.; Hu, R.; Kong, A. N. Regulation of Nrf2, NF-kappaB, and AP-1 signaling pathways by chemopreventive agents. Antioxid. Redox. Signal., 2005, 7(11-12), 1648-63.
55. Shu, L.; Cheung, K. L.; Khor, T. O.; Chen, C.; Kong, A. N. Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev., 29(3), 483-502.
56. Kwon, K. H.; Barve, A.; Yu, S.; Huang, M. T.; Kong, A. N. Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models. Acta Pharmacol. Sin., 2007, 28(9), 1409-21.
57. Shen, G.; Xu, C.; Hu, R.; Jain, M. R.; Nair, S.; Lin, W.; Yang, C. S.; Chan, J. Y.; Kong, A. N. Comparison of (-)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Pharm. Res., 2005, 22(11), 1805-20.
58. Nair, S.; Li, W.; Kong, A. N. Natural dietary anti-cancer chemopreventive compounds: redox-mediated differential signaling mechanisms in cytoprotection of normal cells versus cytotoxicity in tumor cells. Acta Pharmacol. Sin., 2007, 28(4), 459-72.
59. Khor, T. O.; Yu, S.; Barve, A.; Hao, X.; Hong, J. L.; Lin, W.; Foster, B.; Huang, M. T.; Newmark, H. L.; Kong, A. N. Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model. Cancer Res., 2009, 69(17), 7096-102.
60. Keum, Y. S.; Jeong, W. S.; Kong, A. N. Chemopreventive functions of isothiocyanates. Drug News Perspect., 2005, 18(7), 445-51.
61. Lin, W.; Wu, R. T.; Wu, T.; Khor, T. O.; Wang, H.; Kong, A. N. Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem. Pharmacol., 2008, 76(8), 967-73.
62. Hu, R.; Xu, C.; Shen, G.; Jain, M. R.; Khor, T. O.; Gopalkrishnan, A.; Lin, W.; Reddy, B.; Chan, J. Y.; Kong, A. N. Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life Sci., 2006, 79(20), 1944-55.
63. Jeong, W. S.; Keum, Y. S.; Chen, C.; Jain, M. R.; Shen, G.; Kim, J. H.; Li, W.; Kong, A. N. Differential expression and stability of endogenous nuclear factor E2-related factor 2 (Nrf2) by natural chemopreventive compounds in HepG2 human hepatoma cells. J. Biochem. Mol. Biol., 2005, 38(2), 167-76.
64. Nair, S.; Barve, A.; Khor, T. O.; Shen, G. X.; Lin, W.; Chan, J. Y.; Cai, L.; Kong, A. N. Regulation of Nrf2-and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. Acta Pharmacol. Sin., 31(9), 1223-40.
65. Barve, A.; Khor, T. O.; Nair, S.; Reuhl, K.; Suh, N.; Reddy, B.; Newmark, H.; Kong, A. N. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int. J. Cancer, 2009, 124(7), 1693-9.
66. Chen, C.; Shen, G.; Hebbar, V.; Hu, R.; Owuor, E. D.; Kong, A. N. Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis, 2003, 24(8), 1369-78.
67. Jeong, W. S.; Kim, I. W.; Hu, R.; Kong, A. N. Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line. Pharm. Res., 2004, 21(4), 649-60.
68. Keum, Y. S.; Khor, T. O.; Lin, W.; Shen, G.; Kwon, K. H.; Barve, A.; Li, W.; Kong, A. N. Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm. Res., 2009, 26(10), 2324-31.
69. Lii, C. K.; Liu, K. L.; Cheng, Y. P.; Lin, A. H.; Chen, H. W.; Tsai, C. W. Sulforaphane and alpha-lipoic acid upregulate the expression of the pi class of glutathione S-transferase through c-jun and Nrf2 activation. J. Nutr., 140(5), 885-92.
70. Danilov, C. A.; Chandrasekaran, K.; Racz, J.; Soane, L.; Zielke, C.; Fiskum, G. Sulforaphane protects astrocytes against oxidative stress and delayed death caused by oxygen and glucose deprivation. Glia, 2009, 57(6), 645-56.
71. Yeh, C. T.; Chiu, H. F.; Yen, G. C., Protective effect of sulforaphane on indomethacin-induced cytotoxicity via heme oxygenase-1 expression in human intestinal Int 407 cells. Mol. Nutr. Food Res., 2009, 53(9), 1166-76.
72. Nishinaka, T.; Ichijo, Y.; Ito, M.; Kimura, M.; Katsuyama, M.; Iwata, K.; Miura, T.; Terada, T.; Yabe-Nishimura, C. Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. Toxicol. Lett., 2007, 170(3), 238-47.
73. Shen, S. Q.; Zhang, Y.; Xiang, J. J.; Xiong, C. L. Protective effect of curcumin against liver warm ischemia/reperfusion injury in rat model is associated with regulation of heat shock protein and antioxidant enzymes. World J. Gastroenterol., 2007, 13(13), 1953-61.
74. Sharma, V.; Nehru, B.; Munshi, A.; Jyothy, A. Antioxidant potential of curcumin against oxidative insult induced by pentylenetetrazol in epileptic rats. Methods Find Exp. Clin. Pharmacol., 2010, 32(4), 227-32.
75. Barve, A.; Khor, T. O.; Hao, X.; Keum, Y. S.; Yang, C. S.; Reddy, B.; Kong, A. N. Murine prostate cancer inhibition by dietary phytochemicals-curcumin and phenyethylisothiocyanate. Pharm. Res., 2008, 25(9), 2181-9.
76. Khor, T. O.; Huang, Y.; Wu, T.-Y.; Shu, L.; Lee, J.; Kong, A.-N. T. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem.Pharmacol., 2011, 82(9), 1073-1078.
77. Dashwood, R. H.; Ho, E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin. Cancer Biol., 2007, 17(5), 363-9.
78. Li, Y.; Tollefsbol, T. O. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr. Med. Chem., 2010, 17(20), 2141-51.
79. Huang, J.; Plass, C.; Gerhauser, C. Cancer Chemoprevention by Targeting the Epigenome. Curr. Drug Targets, 2010, 12(13), 1925-56.
80. Moaven, O.; Raziee, H. R.; Sima, H. R.; Ganji, A.; Malekzadeh, R.; A'Rabi, A.; Abdollahi, A.; Memar, B.; Sotoudeh, M.; Naseh, H.; Nekoui, N.; Razavipour, A.; Gholamin, M.; Dadkhah, E.; Farshchian, M.; Abbaszadegan, M. R. Interactions between Glutathione-S-Transferase M1, T1 and P1 polymorphisms and smoking, and increased susceptibility to esophageal squamous cell carcinoma. Cancer Epidemiol., 34(3), 285-90.
81. White, D. L.; Li, D.; Nurgalieva, Z.; El-Serag, H. B. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am. J. Epidemiol., 2008, 167(4), 377-89.
82. Bolt, H. M.; Thier, R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr. Drug Metab., 2006, 7(6), 613-28.